Terminé
DoReaL
To evaluate the virologic efficacy, at week 48 and at the 200 copies/mL threshold, of a first-line antiretroviral therapy (ART) regimen based on dolutegravir (DTG) as a follow-up to a first-line regimen based on non-nucleoside reverse transcriptase inhibitors (NNRTIs) under …
Project Details
Principal Investigator
Hagera BOUSEBHA
Duration
24 months
Sponsor
ANRS MIE (ANRS 12427)
Study start
01 Nov 2022
Objectives
Main Objectives
To evaluate the virologic efficacy, at week 48 and at the 200 copies/mL threshold, of a first-line antiretroviral therapy (ART) regimen based on dolutegravir (DTG) as a follow-up to a first-line regimen based on non-nucleoside reverse transcriptase inhibitors (NNRTIs) under real-world conditions in national programs in the Global South, among patients infected with HIV-1.
Research Team
The research team has not yet been filled in for this project.
Collaborate with us
We are open to partnerships with international research institutions and doctoral students.
Research Request
Estimated response time: 3-5 business days.
Keywords
OPERATIONS RESEARCH
OUR PROJECTS
